抗骨质疏松药物对骨质疏松性椎体骨折后再骨折预防的影响:系统综述与Meta分析
该系统综述与Meta分析纳入33项研究,评估抗骨质疏松药物对已有骨质疏松性椎体骨折成人患者再骨折预防的效果。双膦酸盐与较低后续椎体骨折率相关,特立帕肽可能被视为再骨折预防的首选选择,罗莫索单抗在椎体增强术后患者中显示潜在获益但证据有限。
要点
- 双膦酸盐与对照组相比与1年、3年及最终随访时较低的后续椎体骨折率相关。
- 特立帕肽与对照组及双膦酸盐相比与较低的后续椎体骨折率相关。
- 罗莫索单抗在椎体增强术后患者中与双膦酸盐相比与较低的后续椎体骨折率相关,但证据有限。
核心结论
- 特立帕肽可能被视为骨质疏松性椎体骨折患者再骨折预防的首选选择。
- 罗莫索单抗在椎体增强术后患者中显示潜在获益,但支持证据有限。
- 当合成代谢药物不可用或有禁忌时,双膦酸盐可能仍是合理选择。
研究设计与样本
- 按照PRISMA指南系统检索PubMED、Cochrane Library和EMBASE,由两名评价者独立筛选和评估相关研究。
- 共纳入33项研究,进行Meta分析以检验抗骨质疏松药物对已有骨质疏松性椎体骨折成人患者再骨折预防的效果。
主要发现
- 与对照组相比,双膦酸盐与较低的后续椎体骨折率相关:1年OR=0.29(95%CI=0.20-0.43),3年OR=0.51(95%CI=0.42-0.62),最终随访OR=0.35(95%CI=0.26-0.48)。
- 与对照组相比,双膦酸盐与较大的骨密度百分比变化相关:1年MD=3.65(95%CI=2.63-4.67),2年MD=5.39(95%CI=3.87-6.92),3年MD=5.44(95%CI=4.38-6.51)。
- 与对照组相比,双膦酸盐与改善的VAS评分相关:6个月MD=-0.41(95%CI=-0.67,-0.14),12个月MD=-0.92(95%CI=-1.25,-0.59);与改善的ODI评分相关:12个月SMD=-1.89(95%CI=-3.07,-0.71)。
- 与对照组相比,特立帕肽与较低的后续椎体骨折率相关(OR=0.39,95%CI=0.16-0.97);与双膦酸盐相比,特立帕肽与较低的后续椎体骨折率相关(OR=0.41,95%CI=0.30-0.56),并与改善的3个月VAS评分相关(MD=-1.41,95%CI=-2.47,-0.35)。
- 与对照组相比,维生素D与改善的3个月RMDQ评分相关(MD=-1.59,95%CI=-2.88,-0.31);在椎体增强术后患者中,与双膦酸盐相比,罗莫索单抗与较低的后续椎体骨折率相关(OR=0.21,95%CI=0.09-0.51)。
临床怎么用
- 作者认为,特立帕肽可能被视为骨质疏松性椎体骨折患者再骨折预防的首选选择。
- 作者指出,罗莫索单抗在椎体增强术后患者中显示潜在获益,但支持证据有限。
- 作者认为,当合成代谢药物不可用或有禁忌时,双膦酸盐可能仍是合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporotic vertebral fractures (OVFs) increase mortality and impair patients' quality of life. Previous studies have focused on the effects of anti-osteoporosis drugs for primary fracture prevention; however, their role in secondary prevention remains insufficiently explored. Since refractures lead to more serious health issues and are strongly associated with prior fractures and low bone mineral density (BMD), effective treatment strategies for patients with existing OVFs are crucial. A systematic search was conducted using PubMED, Cochrane Library, and EMBASE according to PRISMA guidelines. Two reviewers independently selected and assessed relevant studies. A meta-analysis was conducted to examine the effects of anti-osteoporosis medications on refracture prevention in adult patients with existing OVFs. A total of 33 studies were included in the analysis. Compared to the control, bisphosphonates were associated with lower subsequent vertebral fracture (VF) rates at 1 year [OR = 0.29, 95% CI = 0.20-0.43], 3 years [OR = 0.51, 95% CI = 0.42-0.62], and final follow-up [OR = 0.35, 95% CI = 0.26-0.48]; greater BMD percent changes at 1 year [MD = 3.65, 95% CI = 2.63-4.67], 2 years [MD = 5.39, 95% CI = 3.87-6.92], and 3 years [MD = 5.44, 95% CI = 4.38-6.51]; improved VAS scores at 6 months [MD (95% CI) = -0.41 (-0.67, -0.14)] and 12 months [MD (95% CI) = -0.92 (-1.25, -0.59)]; and improved ODI scores at 12 months [SMD (95% CI) = -1.89 (-3.07, -0.71)]. Teriparatide was associated with lower subsequent VF rates compared to the control [OR = 0.39, 95% CI = 0.16-0.97] and bisphosphonates [OR = 0.41, 95% CI = 0.30-0.56], and led to improved VAS scores at 3 months [MD (95% CI) = -1.41 (-2.47, -0.35)] compared to bisphosphonates. Vitamin D improved RMDQ scores at 3 months [MD (95% CI) = -1.59 (-2.88, -0.31)] compared to the control. Additionally, romosozumab was associated with lower subsequent VF rates compared to bisphosphonates in patients undergoing vertebral augmentation [OR = 0.21, 95% CI = 0.09-0.51]. Teriparatide may be considered a preferred option for secondary fracture prevention in patients with OVFs. Romosozumab demonstrated potential benefit in patients after vertebral augmentation, although the supporting evidence is limited. Bisphosphonates may remain a reasonable alternative when anabolic agents are unavailable or contraindicated.
引用
- Jin H, Jin H, Suk KS, et al. Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis. Osteoporos Int. 2025. PMID: 40846898. doi:10.1007/s00198-025-07661-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。